These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29769245)

  • 1. PI3K/Akt/mTOR Signaling Pathway and the Biphasic Effect of Arsenic in Carcinogenesis.
    Chen QY; Costa M
    Mol Pharmacol; 2018 Jul; 94(1):784-792. PubMed ID: 29769245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).
    Li Z; Lu Y; Ahmad N; Strebhardt K; Liu X
    Cell Cycle; 2015; 14(19):3030-9. PubMed ID: 26292025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice.
    Wang F; Ma H; Liu Z; Huang W; Xu X; Zhang X
    Biomed Pharmacother; 2017 Aug; 92():672-680. PubMed ID: 28582759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper or/and arsenic induces autophagy by oxidative stress-related PI3K/AKT/mTOR pathways and cascaded mitochondrial fission in chicken skeletal muscle.
    Wang Y; Zhao H; Shao Y; Liu J; Li J; Luo L; Xing M
    J Inorg Biochem; 2018 Nov; 188():1-8. PubMed ID: 30096535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between elemental imbalance-related PI3K/Akt/mTOR-regulated apoptosis and autophagy in arsenic (III)-induced jejunum toxicity of chicken.
    Wang Y; Zhao H; Shao Y; Liu J; Li J; Xing M
    Environ Sci Pollut Res Int; 2018 Jul; 25(19):18662-18672. PubMed ID: 29705899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent studies on PI3K/AKT/mTOR signaling pathway in hematopoietic stem cells].
    Zhang YC; Cheng T; Yuan WP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):245-9. PubMed ID: 23484729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis.
    Giacoppo S; Pollastro F; Grassi G; Bramanti P; Mazzon E
    Fitoterapia; 2017 Jan; 116():77-84. PubMed ID: 27890794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer.
    Malla R; Ashby CR; Narayanan NK; Narayanan B; Faridi JS; Tiwari AK
    Biochem Biophys Res Commun; 2015 Jul; 463(3):161-6. PubMed ID: 26003731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of endoplasmic reticulum stress on autophagy and apoptosis of human leukemia cells via inhibition of the PI3K/AKT/mTOR signaling pathway.
    Li LJ; Chai Y; Guo XJ; Chu SL; Zhang LS
    Mol Med Rep; 2018 Jun; 17(6):7886-7892. PubMed ID: 29620275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
    Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
    Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
    Brenner AK; Andersson Tvedt TH; Bruserud Ø
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.
    Chamcheu JC; Adhami VM; Esnault S; Sechi M; Siddiqui IA; Satyshur KA; Syed DN; Dodwad SM; Chaves-Rodriquez MI; Longley BJ; Wood GS; Mukhtar H
    Antioxid Redox Signal; 2017 Jan; 26(2):49-69. PubMed ID: 27393705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PirB inhibits axonal outgrowth via the PI3K/Akt/mTOR signaling pathway.
    Bi YY; Quan Y
    Mol Med Rep; 2018 Jan; 17(1):1093-1098. PubMed ID: 29115495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
    Blachly JS; Baiocchi RA
    Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.
    Lien EC; Lyssiotis CA; Cantley LC
    Recent Results Cancer Res; 2016; 207():39-72. PubMed ID: 27557534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
    Sathe A; Nawroth R
    Methods Mol Biol; 2018; 1655():335-350. PubMed ID: 28889395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.